title: DeltaFosB in brain reward circuits mediates resilience to stress and antidepressant responses.
abstract: In contrast with the many studies of stress effects on the brain, relatively little is known about the molecular mechanisms of resilience, the ability of some individuals to escape the deleterious effects of stress. We found that the transcription factor DeltaFosB mediates an essential mechanism of resilience in mice. Induction of DeltaFosB in the nucleus accumbens, an important brain reward-associated region, in response to chronic social defeat stress was both necessary and sufficient for resilience. DeltaFosB induction was also required for the standard antidepressant fluoxetine to reverse behavioral pathology induced by social defeat. DeltaFosB produced these effects through induction of the GluR2 AMPA glutamate receptor subunit, which decreased the responsiveness of nucleus accumbens neurons to glutamate, and through other synaptic proteins. Together, these findings establish a previously unknown molecular pathway underlying both resilience and antidepressant action.
authors.affiliation: Fishberg Department of Neuroscience, Mount Sinai School of Medicine, New York, New York, USA.
authors.forename: Vincent
authors.initials: V
authors.lastname: Vialou
authors.forename: Alfred J
authors.initials: AJ
authors.lastname: Robison
authors.forename: Quincey C
authors.initials: QC
authors.lastname: Laplant
authors.forename: Herbert E
authors.initials: HE
authors.lastname: Covington
authors.forename: David M
authors.initials: DM
authors.lastname: Dietz
authors.forename: Yoshinori N
authors.initials: YN
authors.lastname: Ohnishi
authors.forename: Ezekiell
authors.initials: E
authors.lastname: Mouzon
authors.forename: Augustus J
authors.initials: AJ
authors.lastname: Rush
authors.forename: Emily L
authors.initials: EL
authors.lastname: Watts
authors.forename: Deanna L
authors.initials: DL
authors.lastname: Wallace
authors.forename: Sergio D
authors.initials: SD
authors.lastname: Iñiguez
authors.forename: Yoko H
authors.initials: YH
authors.lastname: Ohnishi
authors.forename: Michel A
authors.initials: MA
authors.lastname: Steiner
authors.forename: Brandon L
authors.initials: BL
authors.lastname: Warren
authors.forename: Vaishnav
authors.initials: V
authors.lastname: Krishnan
authors.forename: Carlos A
authors.initials: CA
authors.lastname: Bolaños
authors.forename: Rachael L
authors.initials: RL
authors.lastname: Neve
authors.forename: Subroto
authors.initials: S
authors.lastname: Ghose
authors.forename: Olivier
authors.initials: O
authors.lastname: Berton
authors.forename: Carol A
authors.initials: CA
authors.lastname: Tamminga
authors.forename: Eric J
authors.initials: EJ
authors.lastname: Nestler
mesh_terms: D000818:Animals; D000928:Antidepressive Agents / Q000494:pharmacology*; D002908:Chronic Disease; D004291:Dominance-Subordination; D005473:Fluoxetine / Q000494:pharmacology; D018698:Glutamic Acid / Q000378:metabolism; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D008822:Mice, Transgenic; D009474:Neurons / Q000187:drug effects / Q000378:metabolism; D009714:Nucleus Accumbens / Q000187:drug effects / Q000378:metabolism*; D016760:Proto-Oncogene Proteins c-fos / Q000378:metabolism*; D018091:Receptors, AMPA / Q000378:metabolism; D055500:Resilience, Psychological; D012201:Reward; D015398:Signal Transduction; D013315:Stress, Psychological / Q000188:drug therapy* / Q000378:metabolism*; D016896:Treatment Outcome
chemical_list: D000928:Antidepressive Agents; C483819:Fosb protein, mouse; D016760:Proto-Oncogene Proteins c-fos; D018091:Receptors, AMPA; D005473:Fluoxetine; D018698:Glutamic Acid
references.citation: Eur J Neurosci. 2008 May;27(9):2272-84
references.pmid: 18445218
references.citation: Neuropsychopharmacology. 2008 Jan;33(2):368-77
references.pmid: 17429407
references.citation: Ann N Y Acad Sci. 2004 Jun;1018:1-15
references.pmid: 15240347
references.citation: J Neurosci. 2007 Sep 26;27(39):10621-35
references.pmid: 17898233
references.citation: Mol Pharmacol. 1998 Sep;54(3):495-503
references.pmid: 9730908
references.citation: J Neurosci. 2004 Nov 24;24(47):10594-602
references.pmid: 15564575
references.citation: Neuron. 2009 May 14;62(3):335-48
references.pmid: 19447090
references.citation: Neuroscience. 2004;123(4):857-65
references.pmid: 14751279
references.citation: Psychiatry Res. 2009 Apr 30;172(1):75-7
references.pmid: 19243926
references.citation: Physiol Rev. 2007 Jul;87(3):873-904
references.pmid: 17615391
references.citation: J Neurochem. 1999 Jun;72(6):2397-403
references.pmid: 10349849
references.citation: Behav Brain Res. 2005 Jul 1;162(1):127-34
references.pmid: 15922073
references.citation: Nat Neurosci. 2009 Jul;12(7):897-904
references.pmid: 19483686
references.citation: Nat Neurosci. 2008 Mar;11(3):344-53
references.pmid: 18278040
references.citation: Behav Brain Res. 2006 Nov 1;174(1):188-92
references.pmid: 16949682
references.citation: Nat Rev Neurosci. 2009 Jun;10(6):446-57
references.pmid: 19455174
references.citation: Arch Gen Psychiatry. 2005 Nov;62(11):1228-36
references.pmid: 16275810
references.citation: Neuron. 2005 Feb 17;45(4):587-97
references.pmid: 15721244
references.citation: J Neurosci. 2006 Jan 4;26(1):217-22
references.pmid: 16399690
references.citation: Science. 2006 Feb 10;311(5762):864-8
references.pmid: 16469931
references.citation: J Neurosci. 2001 Jan 1;21(1):262-9
references.pmid: 11150343
references.citation: Nature. 2008 Oct 16;455(7215):894-902
references.pmid: 18923511
references.citation: Physiol Behav. 1993 May;53(5):983-93
references.pmid: 8511216
references.citation: Neuron. 2003 Oct 9;40(2):361-79
references.pmid: 14556714
references.citation: Brain Res. 2003 Apr 25;970(1-2):73-86
references.pmid: 12706249
references.citation: Philos Trans R Soc Lond B Biol Sci. 2008 Oct 12;363(1507):3245-55
references.pmid: 18640924
references.citation: J Neurosci. 2009 Sep 16;29(37):11451-60
references.pmid: 19759294
references.citation: Nature. 1999 Sep 16;401(6750):272-6
references.pmid: 10499584
references.citation: J Neuroendocrinol. 1999 Jul;11(7):547-59
references.pmid: 10444312
references.citation: Neuron. 2005 Mar 3;45(5):647-50
references.pmid: 15748840
references.citation: Neuron. 2008 Jul 10;59(1):11-34
references.pmid: 18614026
references.citation: Cell. 2007 Oct 19;131(2):391-404
references.pmid: 17956738
references.citation: Psychopharmacology (Berl). 1997 Apr;130(3):203-12
references.pmid: 9151353
references.citation: Nat Neurosci. 2009 Feb;12(2):200-9
references.pmid: 19151710
references.citation: Neuropsychopharmacology. 2010 Jan;35(1):27-47
references.pmid: 19675534
references.citation: Eur J Neurosci. 2003 May;17(10):2187-200
references.pmid: 12786986
references.citation: Psychopharmacology (Berl). 1995 Sep;121(1):66-72
references.pmid: 8539342
references.citation: Brain Res. 1995 Nov 6;698(1-2):46-52
references.pmid: 8581502
references.citation: Neurosci Biobehav Rev. 1997 Nov;21(6):775-82
references.pmid: 9415902
references.citation: Trends Neurosci. 2007 May;30(5):220-7
references.pmid: 17400299
references.citation: J Neurosci Res. 2008 Oct;86(13):2895-905
references.pmid: 18488994
references.citation: J Neurophysiol. 2009 Jun;101(6):3192-8
references.pmid: 19357347
references.citation: Stress. 2002 Feb;5(1):3-13
references.pmid: 12171762
references.citation: Nature. 2008 Jul 3;454(7200):118-21
references.pmid: 18500330
references.citation: J Neurosci. 2009 Jun 17;29(24):7820-32
references.pmid: 19535594
references.citation: Nat Neurosci. 2003 Nov;6(11):1208-15
references.pmid: 14566342
references.citation: Ann N Y Acad Sci. 2006 Jul;1071:379-96
references.pmid: 16891584
references.citation: Neuroscience. 2003;119(2):557-65
references.pmid: 12770568
references.citation: Nat Neurosci. 2007 Sep;10(9):1116-24
references.pmid: 17726478
references.citation: J Neurosci. 2006 Nov 8;26(45):11665-9
references.pmid: 17093088